Lisa’s annual blood work showed hemoglobin of 11.2 g/dL—mildly below the normal range for women. Her primary care physician noted it, said she should eat more iron-rich foods, and didn’t order further testing. A year later, hemoglobin 10.8. Same advice. The year after, she started feeling genuinely fatigued—not the vague tiredness that everyone has, but the heavy, unrelenting fatigue that made climbing stairs feel like a project. Still hemoglobin 10.6. More iron-food advice. It took her new primary care physician, at a new practice, three minutes to order a ferritin level (never previously checked), a B12 and folate, a reticulocyte count, and a peripheral blood smear. Ferritin was 6 ng/mL—profound iron store depletion. B12 was below the reference range. The anemia she had carried for three years had two causes: iron deficiency driving the small cell picture, and B12 deficiency contributing a macrocytic component that partially masked the full picture on standard indices. Neither cause had been investigated. The treatment she needed was straightforward once the diagnosis was established.
Anemia—hemoglobin below 12 g/dL in women, below 13 g/dL in men—affects approximately 25% of the global population and 10% of adults in developed countries. It is simultaneously overdiagnosed in its significance (mild anemia in older adults is often multifactorial and requires workup rather than alarm) and underinvestigated in its cause (many anemia cases are treated empirically without determining the specific deficiency or mechanism driving the reduction in red blood cell production or survival). The consequence of underinvestigation is treatment of the anemia without addressing the underlying cause — a category error that produces temporary laboratory improvement while the root cause progresses unaddressed. Understanding the diagnostic framework for anemia is essential before any intervention, because the intervention required depends entirely on the cause, and the interventions for different causes are not interchangeable.
The Anemia Diagnostic Framework
Anemia is a sign, not a diagnosis — it indicates that hemoglobin production or red blood cell survival is compromised, but it does not specify why. The differential diagnosis is extensive, and the diagnostic approach is systematic. The most efficient initial framework classifies anemia by red blood cell size (mean corpuscular volume, MCV), which divides the differential into manageable categories:
Normocytic anemia (MCV 80-100 fL): The broadest category. Includes anemia of chronic disease/inflammation (most common cause of normocytic anemia in adults), early iron deficiency or early B12/folate deficiency before MCV changes, hemolytic anemia, aplastic anemia, anemia of chronic kidney disease, hypothyroid anemia, and mixed deficiency anemia (combined iron + B12/folate deficiency that produces a mixed picture that can cancel each other’s MCV effects). Reticulocyte count (measuring whether the bone marrow is responding appropriately) and peripheral blood smear are critical for differentiating causes.
Macrocytic anemia (MCV above 100 fL): Most commonly B12 deficiency, folate deficiency, alcohol (direct macrocytic effect independent of nutritional deficiency), hypothyroidism, or medications (methotrexate, hydroxyurea, zidovudine). B12 deficiency and folate deficiency produce megaloblastic anemia with distinctive hypersegmented neutrophils on peripheral smear. Non-megaloblastic macrocytosis (liver disease, alcohol, hypothyroidism) lacks the hypersegmented neutrophils.
The minimum initial workup for any anemia should include: CBC with differential, reticulocyte count, iron studies (serum iron, TIBC, ferritin), B12, folate, and peripheral blood smear. These tests, costing less than $150 in total, categorize the anemia and identify the most common causes. Additional workup is guided by findings: hemoglobin electrophoresis for thalassemia if microcytic anemia without iron deficiency; LDH and haptoglobin for hemolytic anemia if elevated reticulocytes without blood loss; TSH for hypothyroidism; comprehensive metabolic panel for CKD; bone marrow biopsy if aplastic anemia or myelodysplasia is suspected.
Iron Deficiency: The Most Common Anemia
Iron deficiency anemia affects approximately 1.62 billion people globally — the most common nutritional deficiency disease in human history. In premenopausal women, menstrual blood loss is the primary cause. In men and postmenopausal women, iron deficiency has a pathological cause until proven otherwise — the gastrointestinal tract (occult blood loss from peptic ulcer disease, colorectal polyps, colorectal cancer, celiac disease, IBD) must be evaluated. Assuming dietary iron deficiency in a postmenopausal woman or any man without investigating GI blood loss is a diagnostic error that can delay diagnosis of colorectal cancer by months to years.
Iron absorption physiology determines both why deficiency develops and how to correct it: heme iron (from red meat, poultry, and fish) is absorbed at 15-35% efficiency through a dedicated heme transporter. Non-heme iron (from plant foods, eggs, dairy) is absorbed at 2-20% efficiency through a different pathway dependent on gastric acid for reduction from ferric (Fe3+) to ferrous (Fe2+) form. Vitamin C dramatically increases non-heme iron absorption by maintaining iron in the reduced, absorbable Fe2+ form. Phytates (from whole grains and legumes), tannins (from tea and coffee consumed with meals), and calcium all reduce non-heme iron absorption. Hepcidin — the liver-produced iron regulatory hormone — rises with inflammation and infection and blocks intestinal iron absorption, explaining why iron deficiency anemia of chronic disease does not respond well to oral iron supplementation.
Oral iron supplementation: ferrous sulfate (325mg, providing approximately 65mg elemental iron) three times daily is the traditional standard — highly effective but frequently causes GI side effects (nausea, constipation, black stools) that impair compliance. Ferrous bisglycinate (iron glycinate chelate, 25-36mg elemental iron) has equivalent or superior absorption with significantly better GI tolerability, making it the preferred form for patients with GI sensitivity. Every-other-day iron dosing — recently demonstrated by Moretti et al. (Lancet Haematology, 2015) to produce equivalent or better iron absorption than daily dosing — reduces side effects by avoiding the hepcidin spike that daily iron causes (which transiently reduces subsequent-day absorption). IV iron (ferric carboxymaltose, iron sucrose, iron dextran) bypasses gut absorption limitations and is appropriate when: oral iron is not tolerated, absorption is impaired (celiac disease, IBD, post-bariatric surgery), iron deficit is very large (requiring many months of oral therapy), or rapid correction is needed.
The Anemia Diagnostic Protocol
- Complete the diagnostic workup before treating: Starting oral iron supplementation before determining the cause of anemia is a common but potentially harmful shortcut. In men and postmenopausal women, empirical iron treatment without GI evaluation delays investigation of occult GI blood loss. Iron supplementation can temporarily improve hemoglobin while colorectal cancer or peptic ulcer disease progresses undetected. The rule: determine the cause of iron deficiency before treating it. In premenopausal women with typical menstrual history and no other symptoms, empirical treatment is more defensible but testing is still preferred when ferritin is severely depleted.
- Correct iron deficiency completely: The hemoglobin target is only half the correction goal. Iron stores must also be repleted. Hemoglobin normalizes when iron stores reach approximately 500mg — but total body iron repletion requires stores to reach 1,000-1,200mg. Stopping iron supplementation when hemoglobin normalizes (typically after 6-8 weeks) without continuing for an additional 3 months to replete stores ensures rapid redepletion. The ferritin target after iron repletion: 50-100 ng/mL (not just above the lower limit of normal at 12-15 ng/mL).
- Evaluate B12 status thoroughly: B12 deficiency affects approximately 6% of adults under 60 and 20% of those over 60. Causes include: pernicious anemia (autoimmune destruction of intrinsic factor-producing parietal cells), vegetarian/vegan diet (B12 is found only in animal foods), metformin use (impairs ileal B12 absorption in 10-15% of users after years of use), proton pump inhibitor use (reduces gastric acid required to cleave protein-bound B12 from food), ileal disease or resection (intrinsic factor receptor location). Serum B12 alone is an insensitive marker — significant tissue deficiency can exist with serum B12 in the low-normal range. Methylmalonic acid (MMA) and homocysteine are more sensitive functional markers of B12 status; elevated MMA with low-normal B12 indicates functional deficiency requiring treatment.
- Assess folate status and MTHFR variant: Folate deficiency causes megaloblastic anemia identical to B12 deficiency on peripheral smear — the critical distinction is that treating B12 deficiency with folate can temporarily correct the hematological picture while neurological B12 deficiency continues to progress. Always test both. Folate status is assessed by serum folate (reflecting recent intake) and red blood cell folate (reflecting longer-term stores). The MTHFR C677T variant (present in 10-15% of the population in homozygous form) impairs folic acid conversion to the active 5-methyltetrahydrofolate — these patients benefit from methylfolate (5-MTHF) supplementation rather than standard folic acid.
- Optimize dietary iron absorption: For patients with dietary iron deficiency from vegetarian/vegan diets or inadequate meat intake, practical dietary interventions substantially improve iron status. Consuming vitamin C (bell peppers, citrus, strawberries) with every iron-containing meal increases non-heme iron absorption by 2-4 fold. Avoiding tea, coffee, and calcium-containing foods with iron-rich meals removes inhibitors. Cooking in cast iron cookware leaches iron into food — one study found cast iron cooking of acidic foods (tomato sauce) increased food iron content by 7-fold. Fermentation of phytate-containing grains and legumes (sourdough, fermented dal) reduces phytate content and improves iron bioavailability from these foods.
- Address root causes of iron malabsorption: Celiac disease, atrophic gastritis, Helicobacter pylori infection, and inflammatory bowel disease all impair iron absorption. When iron deficiency is refractory to oral supplementation or recurs rapidly after correction, GI evaluation for these conditions is indicated. H. pylori eradication alone improves iron deficiency anemia in infected patients independent of iron supplementation in multiple RCTs — the bacteria reduces gastric acid and competes for iron, and eradication reverses both effects. Celiac disease treatment (strict GFD) restores normal duodenal iron absorption within months of diagnosis.
- Investigate copper and other trace mineral deficiencies: Copper deficiency causes anemia through its role in iron metabolism — ceruloplasmin (a copper-containing protein) is required for iron export from cells and tissues, and copper deficiency impairs iron mobilization producing functional iron deficiency despite normal or elevated iron stores. Copper deficiency anemia is often misdiagnosed as B12 deficiency or myelodysplasia; it responds to copper supplementation. Causes: excessive zinc supplementation (zinc and copper compete for absorption), post-gastric bypass surgery, malnutrition. Test copper and ceruloplasmin in anemias that don’t respond to iron or B12 as expected.
- Monitor and maintain after correction: Anemia is not resolved when hemoglobin normalizes — the root cause must be addressed to prevent recurrence. For menstrual iron deficiency: ensure ongoing adequate dietary iron, consider hormonal management of heavy menstruation if appropriate. For dietary B12 deficiency in vegans: indefinite supplementation with 1,000-2,000mcg B12 daily (sublingual methylcobalamin preferred for absorption efficiency) or regular IM injections. For pernicious anemia: lifelong quarterly IM B12 injections. For celiac disease: strict GFD adherence and monitoring of iron and B12 status annually.
“Anemia is never the diagnosis—it’s the clue. Finding the hemoglobin number is the beginning of the clinical question, not the answer to it.”
Anemia of Chronic Disease and Inflammation
Anemia of chronic disease (ACD) — now more accurately termed anemia of chronic inflammation — is the second most common anemia after iron deficiency and the most common cause of anemia in hospitalized patients. It occurs in chronic inflammatory conditions (rheumatoid arthritis, lupus, IBD), chronic infections (HIV, tuberculosis, osteomyelitis), cancer, and chronic kidney disease. The mechanism is distinct from nutritional deficiency: hepcidin elevation driven by IL-6 and other cytokines blocks intestinal iron absorption and sequesters iron in macrophages, making iron unavailable for erythropoiesis despite normal or elevated total body iron stores.
The practical diagnostic challenge: ACD can be difficult to distinguish from iron deficiency, and the two can coexist — a patient with RA and menorrhagia may have both ACD from the inflammation and true iron deficiency from blood loss. The laboratory profile helps: ACD typically shows low serum iron with low TIBC (both fall with inflammation), low-normal ferritin (elevated by the acute phase response even in the presence of some iron depletion). Soluble transferrin receptor (sTfR), which is elevated in iron deficiency but not ACD, helps distinguish the two. The sTfR/log ferritin index provides the most reliable differentiation when the two conditions coexist.
Treatment of ACD: primarily addressing the underlying inflammatory condition. When inflammation is controlled, hepcidin normalizes, iron absorption resumes, and anemia resolves. Iron supplementation in pure ACD (without concurrent true iron deficiency) is generally ineffective because the absorbed iron is immediately sequestered by hepcidin-mediated macrophage trapping. IV iron may be effective for ACD with concurrent iron deficiency, bypassing the absorption block. Erythropoiesis-stimulating agents (ESAs) are used for CKD-related ACD when hemoglobin falls below 10 g/dL; their use in other ACD settings is carefully controlled due to cardiovascular and thrombotic risk.
B12 Deficiency: The Hidden Epidemic
The epidemiology of B12 deficiency is poorly appreciated in clinical practice: studies using sensitive functional markers (methylmalonic acid rather than serum B12) suggest that borderline or functional B12 deficiency affects 10-15% of adults under 60 and 20-30% of those over 60. The neurological consequences of B12 deficiency — subacute combined degeneration of the spinal cord, peripheral neuropathy, cognitive impairment — can occur before anemia develops and are only partially reversible with treatment. Early detection and correction of B12 deficiency before neurological symptoms develop prevents irreversible damage.
Metformin-associated B12 depletion deserves specific attention given the drug’s widespread use in type 2 diabetes. Approximately 10-15% of long-term metformin users develop significant B12 deficiency from metformin’s interference with calcium-dependent binding of the intrinsic factor-B12 complex to ileal receptors. The deficiency develops insidiously over years of use and is commonly misattributed to diabetic neuropathy — the overlapping symptoms of metformin-induced B12 deficiency neuropathy and diabetic peripheral neuropathy create a diagnostic trap. Annual B12 testing in all metformin users is recommended; supplementation with methylcobalamin 1,000mcg daily is inexpensive insurance against metformin’s B12-depleting effect.
Proton pump inhibitor-associated B12 depletion is similarly underappreciated. Gastric acid is required to cleave food-protein-bound B12 from the protein before intrinsic factor can bind it; PPIs suppressing gastric acid impair this step, reducing B12 absorption from food. Long-term PPI users (>2 years) should have annual B12 testing. The depletion is less severe than pernicious anemia because crystalline B12 in supplements (not protein-bound) can still be absorbed via passive diffusion in the intestinal mucosa without requiring intrinsic factor — oral B12 supplementation at 1,000-2,000mcg daily is effective for PPI-associated depletion even when pernicious anemia-level deficiency is not present.
Lisa’s Resolution
Lisa’s treatment after proper diagnosis was straightforward: IV iron infusion to rapidly correct her severely depleted iron stores (ferritin from 6 to 87 ng/mL in eight weeks), followed by oral iron bisglycinate 36mg daily for three additional months to maintain iron repletion. Intramuscular B12 injections weekly for four weeks, then monthly maintenance for six months, then transition to high-dose oral methylcobalamin 1,000mcg daily (her B12 deficiency was from inadequate dietary intake — she had been vegetarian for seven years, not from pernicious anemia, so oral supplementation could maintain adequate levels after stores were repleted). Upper and lower GI evaluation was performed given the severity of her iron deficiency; it was negative, confirming the dietary and vegetarian-diet etiology.
At six months, her hemoglobin was 13.4 g/dL — well within normal range — ferritin was 74 ng/mL, and B12 was 612 pg/mL. More meaningfully, the fatigue that had dominated her daily experience for two years was gone. She now maintains daily methylcobalamin supplementation, eats iron-rich foods (lentils, tofu, leafy greens) with vitamin C at each meal, and has annual B12 and ferritin testing. The three years of managed anemia without investigation were not just a missed treatment opportunity — they produced three years of reduced quality of life that targeted workup and directed treatment resolved in six months.
FAQ
Q: Can I get enough iron from a plant-based diet?
Yes, with attention to food choices and absorption optimization. Plant foods provide non-heme iron, which is less bioavailable than heme iron but can meet requirements with appropriate dietary strategies. Best plant iron sources: lentils (6.6mg per cup cooked), chickpeas (4.7mg per cup), fortified cereals (varies), tofu (3.4mg per 100g), spinach (3.6mg per 100g — with the caveat that spinach oxalate reduces its absorption), dark chocolate (3.4mg per ounce), pumpkin seeds (8.8mg per ounce). Maximize non-heme iron absorption: always consume with vitamin C, cook in cast iron for acidic foods, avoid tea and coffee for 30 minutes before and after iron-rich meals, soak and cook legumes to reduce phytate. Vegetarians and vegans should monitor ferritin annually and supplement if stores are suboptimal.
Q: What’s the difference between iron deficiency and iron deficiency anemia?
Iron deficiency anemia is the late stage of a depletion process that begins with depleted iron stores (low ferritin) before hemoglobin falls. The stages: depleted iron stores (low ferritin, normal hemoglobin) → iron-deficient erythropoiesis (low ferritin, elevated sTfR, normal or low-normal hemoglobin, early microcytosis) → iron deficiency anemia (low ferritin, low hemoglobin, microcytic red cells). Symptoms — fatigue, reduced exercise tolerance, cognitive effects, hair loss — can occur at the depleted stores stage before anemia develops. Treating when ferritin is low but hemoglobin is still normal prevents progression to anemia and addresses symptoms earlier. Ferritin below 30 ng/mL warrants investigation and treatment even with normal hemoglobin.
Q: Why is my doctor checking hemoglobin but not running a ferritin test?
Ferritin is not always included in standard annual bloodwork unless specifically ordered. Hemoglobin is measured on a standard CBC; ferritin requires a separate order. Standard practice variation means some physicians order ferritin routinely with iron deficiency evaluation and others rely on serum iron and TIBC without ferritin — despite ferritin being the most sensitive and specific marker of iron stores. If a CBC shows low-normal or below-normal hemoglobin and a ferritin hasn’t been ordered, requesting one specifically is reasonable. If ferritin has been checked and sits in the low-normal range (12-30 ng/mL), it may still be functionally depleted — the “normal” range extends below optimal, and symptoms of iron deficiency can occur with ferritin in the 12-30 range that is technically within the reference interval.
Q: Should I take iron supplements daily or every other day?
The every-other-day protocol (recently established in clinical research) is supported by the biology of hepcidin regulation. Daily iron dosing causes a hepcidin spike approximately 6 hours after the dose that reduces iron absorption from subsequent doses the same day and the following day. Every-other-day dosing allows hepcidin to return to baseline before the next dose, producing equivalent or better total iron absorption with half the doses and significantly fewer GI side effects. For patients who tolerate daily iron without significant side effects and need rapid repletion, daily dosing is still appropriate. For those with GI sensitivity or for maintenance supplementation, every-other-day dosing is a validated, research-supported approach that improves tolerability without reducing efficacy.
Q: Can exercise affect my iron levels?
Yes, significantly. Endurance athletes — particularly distance runners and female athletes — are at elevated iron deficiency risk through multiple mechanisms. Foot-strike hemolysis (red blood cell destruction from the mechanical impact of running on hard surfaces) increases iron loss. Increased GI bleeding from running (exercise-induced gut ischemia causes minor GI mucosal damage). Increased sweat losses of iron. Elevated hepcidin from exercise-induced inflammation transiently reduces iron absorption in the hours after intense training. Female athletes with menstrual losses plus these athlete-specific iron losses face cumulative deficits that can be significant. Athletes should monitor ferritin semi-annually and ensure dietary iron intake and absorption are optimized. Sports-related iron deficiency without anemia — the most common athlete presentation — impairs aerobic performance and training adaptation before hemoglobin falls.
Hemolytic Anemia: When Red Cells Are Destroyed Too Quickly
Hemolytic anemia — anemia caused by premature destruction of red blood cells — requires a completely different diagnostic and management approach than nutritional deficiency anemias. The bone marrow’s response to red cell destruction is increased production, reflected by elevated reticulocyte count. When reticulocytes are disproportionately high relative to the degree of anemia, hemolysis should be suspected. The laboratory picture: elevated LDH (released from lysed red cells), low haptoglobin (consumed by hemoglobin-haptoglobin complexes cleared by the liver), elevated indirect bilirubin (from hemoglobin breakdown), and elevated reticulocyte count.
Hemolytic anemias divide into intrinsic (red cell defects) and extrinsic (immune or mechanical) categories. Intrinsic causes: hereditary spherocytosis (membrane defect), G6PD deficiency (enzyme defect — important for male patients with Mediterranean, African, or Middle Eastern ancestry who develop acute hemolysis with oxidant stress from infections, fava beans, or certain medications), sickle cell disease and trait, and thalassemia (the major hemoglobin disorders). Extrinsic causes: autoimmune hemolytic anemia (warm or cold antibody types, from lymphoma, lupus, or medications), microangiopathic hemolytic anemia (TTP, HUS, DIC — medical emergencies), and mechanical causes (heart valve hemolysis, exercise-induced hemolysis in runners).
The clinical importance of identifying hemolysis: treating hemolytic anemia with iron or B12 supplementation (as if it were deficiency anemia) does not address the problem and delays diagnosis. G6PD deficiency is particularly important to identify because the hemolytic crisis it causes with oxidant exposure (including medications like dapsone, primaquine, nitrofurantoin, and some sulfonamides — and foods like fava beans) can be life-threatening and is entirely preventable with awareness. The peripheral blood smear is critical for hemolysis evaluation: spherocytes (hereditary spherocytosis, autoimmune hemolysis), schistocytes (fragmented cells from microangiopathy), sickle cells, target cells, and bite cells (G6PD deficiency) each tell the story of the mechanism.
Anemia in Specific Populations: Tailored Approaches
Anemia management requires population-specific considerations because the most common causes, the appropriate workup, and the treatment options vary significantly across demographic groups.
Premenopausal women: Menstrual blood loss is the most common cause of iron deficiency. The average menstrual loss is 35-40ml, but women with heavy menstrual bleeding (more than 80ml per cycle, or frequent pad/tampon changes throughout the day) lose significantly more. Heavy menstrual bleeding affects approximately 25% of premenopausal women and is the most common cause of severe iron deficiency in this population. Gynecological evaluation for causes of heavy menstrual bleeding (uterine fibroids, adenomyosis, endometrial pathology) and consideration of hormonal management to reduce blood loss addresses the root cause in a way that indefinite iron supplementation does not.
Pregnant women: Iron requirements approximately double during pregnancy as blood volume expands and fetal iron needs are met. Iron deficiency anemia in pregnancy is associated with preterm birth, low birth weight, and postpartum depression. Ferritin should be checked at the first prenatal visit and supplementation initiated immediately if below 30 ng/mL. Standard prenatal vitamins typically provide 27mg elemental iron daily, which is insufficient for women with depleted stores who need repletion, not just maintenance.
Older adults: Anemia in adults over 65 is classified as nutritional (iron, B12, folate deficiency — one-third of cases), anemia of chronic disease (one-third), or unexplained anemia of aging (one-third). Unexplained anemia of aging reflects the gradual decline in erythropoietic reserve with aging without identifiable specific cause — it has worse outcomes in prospective studies than nutritional or ACD anemia, including higher all-cause mortality. Anemia in older adults should never be dismissed as “normal aging” without a workup confirming the cause; nutritional deficiencies are common, treatable, and easily missed without specific testing.
Post-bariatric surgery patients: Gastric bypass surgery produces multiple nutritional deficiencies including iron, B12, folate, copper, and zinc deficiency that require lifelong monitoring and supplementation. The gastric anatomy changes dramatically reduce acid secretion and the volume of gastric secretions required for iron and B12 absorption. Lifetime mandatory annual micronutrient monitoring and supplementation with bariatric-specific formulations (iron, B12, folate, calcium, vitamin D, zinc, copper) is the standard of care. Iron deficiency is the most common post-bariatric nutritional complication, affecting up to 50% of patients at five years without aggressive supplementation.
Nutritional Optimization for Anemia Prevention
Beyond the clinical management of established anemia, optimizing nutritional status to prevent iron and B12 deficiency is straightforward and accessible. The key dietary strategies that maintain iron and B12 status across populations:
For iron maintenance: Include a heme iron source (red meat, poultry, or fish) two to three times weekly if omnivorous — heme iron absorption is much more reliable than non-heme and provides the most efficient dietary iron source. For vegetarians and vegans: daily inclusion of iron-rich plant foods (lentils, chickpeas, tofu, dark leafy greens, pumpkin seeds) combined with vitamin C at every iron-containing meal. Monitor ferritin annually; supplement if ferritin trends below 50 ng/mL. Cook with cast iron for acidic foods to increase dietary iron contribution from cookware.
For B12 maintenance: Animal foods provide B12 exclusively — omnivores who eat meat, fish, dairy, and eggs regularly rarely develop dietary B12 deficiency. Vegans and strict vegetarians require supplementation: 1,000-2,000mcg methylcobalamin daily (sublingual for best absorption) or 250mcg cyanocobalamin daily (cyanocobalamin’s longer retention time makes lower doses effective with daily dosing). Nutritional yeast fortified with B12 is an additional dietary source for vegans. Older adults should supplement regardless of dietary pattern due to reduced absorption from age-related changes in gastric acid production and intrinsic factor. Annual B12 testing with methylmalonic acid for functional assessment in at-risk populations.
For folate maintenance: Dark leafy greens (spinach, kale, arugula), lentils, asparagus, avocado, and broccoli are the best dietary folate sources. Cooking destroys a significant portion of folate — lightly cooked vegetables retain more than heavily boiled ones. Standard guidance for women of childbearing age is 400mcg methylfolate daily (not folic acid, for MTHFR variant safety) regardless of dietary folate intake, given the critical role of adequate folate in neural tube development in early pregnancy — often before a woman knows she is pregnant.
The Connection Between Anemia and Other Health Systems
Anemia does not exist in isolation. It’s deeply connected to other body system functions in ways that make it both a consequence of dysfunction elsewhere and a driver of dysfunction in systems that depend on adequate oxygen delivery. Understanding these connections motivates thorough investigation and complete treatment rather than accepting mild anemia as an acceptable baseline.
Thyroid function and anemia: hypothyroidism causes anemia through reduced erythropoietin production and reduced bone marrow sensitivity to erythropoietin. The anemia of hypothyroidism normalizes with thyroid hormone replacement without any specific anemia treatment. Conversely, iron deficiency impairs thyroid hormone synthesis because thyroid peroxidase (the enzyme that incorporates iodine into thyroid hormones) is iron-dependent — iron deficiency is a cause of functional hypothyroidism that responds to iron repletion. This bidirectional relationship means thyroid and iron status should be evaluated together in patients with either condition.
Cognitive function and anemia: iron deficiency specifically impairs cognitive function through its role in myelin synthesis and neurotransmitter production (dopamine, serotonin, and norepinephrine synthesis all require iron). Children with iron deficiency have measurable cognitive impairment that is only partially reversible with iron repletion if deficiency persists through critical developmental periods. In adults, iron deficiency without anemia is associated with cognitive fatigue, reduced working memory, and reduced attention — effects that normalize with iron repletion. The cognitive consequences of iron deficiency are particularly important to address in adolescent girls (in whom iron deficiency is common), pregnant women, and exclusively breastfed infants from iron-deficient mothers.
Exercise capacity and anemia: hemoglobin is the oxygen-carrying molecule that limits aerobic performance. Even mild anemia (hemoglobin 11-12 g/dL in women) measurably reduces maximal aerobic capacity (VO2 max) and submaximal exercise endurance. Iron deficiency without anemia independently impairs exercise capacity through iron’s role in mitochondrial function — the mitochondrial iron-sulfur proteins of the electron transport chain are iron-dependent, and their dysfunction in iron-deficient muscle reduces ATP production efficiency independent of the oxygen-carrying limitation. Athletes who find their performance declining despite adequate training should have ferritin measured alongside hemoglobin — suboptimal iron stores can impair performance before anemia develops.
The Broader Diagnostic Responsibility
Lisa’s three-year diagnostic delay was not caused by medical incompetence. Her original physician correctly identified low hemoglobin and correctly understood that iron-rich foods were beneficial. The failure was diagnostic incompleteness: not pursuing the cause behind the persistently low hemoglobin, not checking the most sensitive iron store marker (ferritin), and not considering B12 deficiency as a concurrent contributor in a seven-year vegetarian. These are not exotic clinical maneuvers. They’re basic workup steps that any physician seeing a patient with persistent anemia should perform.
The systematic lesson: anemia in any patient that fails to respond to initial treatment, or that recurs after treatment, or that persists without clear cause, requires escalation of the diagnostic workup. The tests that Lisa eventually received — ferritin, B12, reticulocyte count, peripheral blood smear — should have been ordered on her first presentation with hemoglobin below normal. The cost of these additional tests is small. The cost of three years of inadequately investigated anemia — in fatigue, reduced quality of life, potential neurological B12 deficiency effects that may require years to fully resolve — is large.
Patients who understand the diagnostic framework for anemia can advocate for complete investigation rather than empirical treatment. The question to ask: “What is the cause of my anemia?” Not “How do we treat my anemia?” The cause determines the treatment. Generic iron supplementation without knowing the cause is treating the lab value, not the patient. And for Lisa, for Greg, for Frank — the people whose stories run through this series — the difference between treating lab values and treating causes is the difference between managing disease and resolving it. The information to demand that difference from a physician exists. Using it is a choice.
When to Refer to a Hematologist
Most cases of anemia in primary care practice are nutritional deficiencies (iron, B12, folate) or anemia of chronic disease that can be diagnosed and managed by a primary care physician with appropriate testing and monitoring. However, certain anemia presentations warrant referral to a hematologist for specialized evaluation:
Anemia that does not respond to appropriate treatment as expected — hemoglobin not improving after six to eight weeks of adequate iron supplementation in iron deficiency, or not responding to B12 treatment in documented B12 deficiency — requires hematology evaluation to identify concurrent causes. Severe anemia (hemoglobin below 8 g/dL) in a stable outpatient warrants urgent specialist evaluation of the cause and management plan. Any suspicion of primary bone marrow disease — myelodysplastic syndrome (MDS), aplastic anemia, hematological malignancy — based on multilineage cytopenia (low red cells, white cells, AND platelets), dysplastic cells on peripheral smear, or unexplained progressive anemia in older adults. Hemolytic anemia of uncertain cause, particularly autoimmune hemolysis requiring immunosuppressive treatment. Thalassemia major or other hemoglobinopathies requiring complex transfusion and chelation management.
The hematology referral should be accompanied by all prior workup results — CBC trends over time, iron studies with dates, B12, folate, reticulocyte counts, and the peripheral blood smear report if available. The hematologist’s additional tools — bone marrow biopsy, flow cytometry, FISH for cytogenetic analysis, specialized hemolysis workup — address the cases that fall beyond the diagnostic capability of standard laboratory testing. Knowing when a case exceeds primary care diagnostic and management capacity, and promptly referring rather than continuing empirical treatment, is itself a clinical skill — one that Lisa’s eventual physician exercised correctly when the full workup revealed an unusual pattern requiring specialist interpretation.
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map